| Trial ID: | L5677 |
| Source ID: | NCT00203632
|
| Associated Drug: |
Rosiglitazone/Placebo
|
| Title: |
Glitazones and Endothelial Function (GATE)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: rosiglitazone/placebo
|
| Outcome Measures: |
Primary: The primary end-point of the study is the percent change in forearm blood flow to acetylcholine in patients randomized to rosiglitazone compared with placebo. | Secondary: Secondary end-points include (i) the percent change in forearm blood flow to verapamil and the absolute change to both acetylcholine and verapamil and (ii) the relationship between HOMA-IR, CRP and endothelial function.
|
| Sponsor/Collaborators: |
Sponsor: University of Calgary | Collaborators: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2003-09
|
| Completion Date: |
2007-10
|
| Results First Posted: |
|
| Last Update Posted: |
2008-11-02
|
| Locations: |
Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00203632
|
